# A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

> **NCT04534283** · PHASE2 · TERMINATED · sponsor: **Anita Turk** · enrollment: 16 (actual)

## Conditions studied

- Cancer
- Cancer Metastatic
- BRAF V600E
- MEK1 Gene Mutation
- MEK2 Gene Mutation
- ERK Mutation
- RAF1 Gene Mutation

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** LY3214996

## Key facts

- **NCT ID:** NCT04534283
- **Lead sponsor:** Anita Turk
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-05
- **Primary completion:** 2023-08-07
- **Final completion:** 2023-08-07
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Lack of efficacy.
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04534283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04534283, "A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04534283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*